CGEM vs. GMTX, TWST, HCM, EWTX, KYMR, AMRX, JANX, ARWR, NAMS, and PTGX
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Gemini Therapeutics (GMTX), Twist Bioscience (TWST), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Kymera Therapeutics (KYMR), Amneal Pharmaceuticals (AMRX), Janux Therapeutics (JANX), Arrowhead Pharmaceuticals (ARWR), NewAmsterdam Pharma (NAMS), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.
Cullinan Therapeutics vs.
Gemini Therapeutics (NASDAQ:GMTX) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500.
Cullinan Therapeutics has a consensus target price of $31.67, indicating a potential upside of 208.64%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Gemini Therapeutics.
75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Cullinan Therapeutics had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 0 mentions for Gemini Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.49 beat Gemini Therapeutics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.
Gemini Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cullinan Therapeutics' return on equity of -26.54% beat Gemini Therapeutics' return on equity.
Cullinan Therapeutics received 23 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Summary
Cullinan Therapeutics beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CGEM) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CGEM Stock Alerts